Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study
by Zacks Equity Research
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
by Zacks Equity Research
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session.
Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $4.50, moving +0.45% from the previous trading session.
Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know
by Zacks Equity Research
Clovis Oncology (CLVS) closed the most recent trading day at $6.17, moving -1.59% from the previous trading session.
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears
by Benjamin Rains
The market selloff might continue amid coronavirus uncertainty. But that doesn't mean investors should stop buying, or adding stocks to their watchlists. Here's how to find strong cheap stocks under $10 to buy...
Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the fourth quarter of 2019 while revenues beat estimates.
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -12.42% and 1.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
Intellia (NTLA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.